PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50122C00061 — PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES

PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES is a federal NONE award for Department of Health and Human Services (HHS) held by MAPP BIOPHARMACEUTICAL, INC.. Estimated value $220.6M ($220.6M obligated). Current period of performance ends Sep 30, 2031 (potential Sep 29, 2032). Last award drew 2 bidders. Place of performance: SAN DIEGO, CA. Related solicitation 75A50121R00038.

$220.6M
Estimated Value
$220.6M
Obligated
Sep 30, 2031
PoP End / Expires
2
Bidders (last award)
More in SCOUT — score this to your firm →See related expiring contracts →

Analysis

Public

MAPP BIOPHARMACEUTICAL, INC. holds $72.2M across 13 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 2 offers. Set-aside status: NONE. Recompete timing centers on the Sep 30, 2031 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75A50122C00061
AgencyDepartment of Health and Human Services (HHS)
IncumbentMAPP BIOPHARMACEUTICAL, INC.
UEIM9V9QTHR1H28
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSC6505
Place of performanceSAN DIEGO, CA
Related solicitation75A50121R00038
PoP end (current)Sep 30, 2031
PoP end (w/ options)Sep 29, 2032
Obligated$220.6M

PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES

Recompete timing

Public
Expiring in 1874 days

Current PoP ends Sep 30, 2031 (1874 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Mar 30, 2030.

Track recompete timing in SCOUT →

Incumbent footprint

Public record

MAPP BIOPHARMACEUTICAL, INC.$72.2M obligated across 13 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($72.2M) · all agencies
Department of Health and Human Services (HHS)$72.1M · 100%Department of Defense (DOD)$92K · 0%
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Score this to your firm — $90 Pilot →

Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. 90 days · $90 · no annual contract · cancel anytime

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open MAPP BIOPHARMACEUTICAL, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50122C00061?

75A50122C00061 (PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES) is a Department of Health and Human Services (HHS) award with an estimated value of $220.6M, currently held by MAPP BIOPHARMACEUTICAL, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50122C00061?

MAPP BIOPHARMACEUTICAL, INC. is the incumbent with $72.2M across 13 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2031.

When does 75A50122C00061 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2031. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50122C00061